Mast cell activation pathways

Mast cell activation pathways encompass the complex intracellular signaling networks that trigger the release of preformed and newly synthesized inflammatory mediators from mast cells. The most prominent pathway is IgE-mediated, where allergen-induced cross-linking of the high-affinity IgE receptor (FcεRI) activates a signalosome involving kinases like Spleen tyrosine kinase (SYK) and Bruton's tyrosine kinase (BTK) [PMC7161534, PMC8003935]. Alternative pathways include activation via the KIT receptor (CD117) by stem cell factor or through the Mas-related G protein-coupled receptor member X2 (MRGPRX2) by various cationic ligands [PMC7161534, J Allergy Clin Immunol 2019]. These pathways are central to the pathophysiology of allergic diseases, asthma, and mast cell activation syndrome (MCAS) [PMC10101453, PMC6461302]. Therapeutic intervention involves stabilizing mast cells, blocking IgE, or inhibiting specific kinases within the signaling network to prevent the release of histamine, leukotrienes, and cytokines [PMC8003935, PMC10101453].

Other names

Mast cell signalingMast cell degranulation pathwaysFcεRI signaling pathwayIgE-mediated activationNon-IgE-mediated mast cell activation

Drugs targeting these pathways act by neutralizing IgE to prevent receptor cross-linking, stabilizing mast cell membranes to prevent mediator release, or inhibiting key signaling kinases such as SYK, BTK, and KIT to block downstream activation cascades [PMC7161534, PMC8003935, PMC10101453].